Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Novak

Showing results (301-310 of 332) with videos related to

Pageof 34
Sort By:
Proteomics. Clinical Applications|February 5, 2010
CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnosticsJoshua J Coon, Petra Zürbig, Mohammed Dakna, et al.
Haematologica|August 5, 2021
Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative studySabine Kayser, Michael Kramer, David Martínez-Cuadrón, et al.
Proteomics. Clinical Applications|December 8, 2010
Clinical proteomics: A need to define the field and to begin to set adequate standardsHarald Mischak, Rolf Apweiler, Rosamonde E Banks, et al.
Journal of the American College of Cardiology|March 9, 2019
Relationships of Overt and Silent Brain Lesions With Cognitive Function in Patients With Atrial FibrillationDavid Conen, Nicolas Rodondi, Andreas Müller, et al.
Brain Communications|April 17, 2025
Current and prospective roles of magnetic resonance imaging in mild traumatic brain injuryMatilde Sassani, Tara Ghafari, Pradeepa R W Arachchige, et al.
Blood Advances|June 5, 2023
Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized studyPierre Fenaux, Marco Gobbi, Patricia L Kropf, et al.
Lancet (London, England)|December 10, 2025
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trialLorenzo Falchi, Marcel Nijland, Huiqiang Huang, et al.
Blood Advances|February 24, 2026
Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapyAndrew H Wei, Panayiotis Panayiotidis, Pau Montesinos, et al.
JCI Insight|February 8, 2022
Immunoglobulin A nephropathy is characterized by anticommensal humoral immune responsesElissa G Currie, Bryan Coburn, Elisa A Porfilio, et al.
Atherosclerosis|June 2, 2024
Advancements in risk stratification and management strategies in primary cardiovascular preventionFotios Barkas, Yusuf Ziya Sener, Pelin Arabacilar Golforoush, et al.
Pageof 34

Showing results (301-310 of 332) with videos related to

Sort By:
Pageof 34
Proteomics. Clinical Applications|February 5, 2010
CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnosticsJoshua J Coon, Petra Zürbig, Mohammed Dakna, et al.
Haematologica|August 5, 2021
Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative studySabine Kayser, Michael Kramer, David Martínez-Cuadrón, et al.
Proteomics. Clinical Applications|December 8, 2010
Clinical proteomics: A need to define the field and to begin to set adequate standardsHarald Mischak, Rolf Apweiler, Rosamonde E Banks, et al.
Journal of the American College of Cardiology|March 9, 2019
Relationships of Overt and Silent Brain Lesions With Cognitive Function in Patients With Atrial FibrillationDavid Conen, Nicolas Rodondi, Andreas Müller, et al.
Brain Communications|April 17, 2025
Current and prospective roles of magnetic resonance imaging in mild traumatic brain injuryMatilde Sassani, Tara Ghafari, Pradeepa R W Arachchige, et al.
Blood Advances|June 5, 2023
Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized studyPierre Fenaux, Marco Gobbi, Patricia L Kropf, et al.
Lancet (London, England)|December 10, 2025
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trialLorenzo Falchi, Marcel Nijland, Huiqiang Huang, et al.
Blood Advances|February 24, 2026
Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapyAndrew H Wei, Panayiotis Panayiotidis, Pau Montesinos, et al.
JCI Insight|February 8, 2022
Immunoglobulin A nephropathy is characterized by anticommensal humoral immune responsesElissa G Currie, Bryan Coburn, Elisa A Porfilio, et al.
Atherosclerosis|June 2, 2024
Advancements in risk stratification and management strategies in primary cardiovascular preventionFotios Barkas, Yusuf Ziya Sener, Pelin Arabacilar Golforoush, et al.
Pageof 34